CellaVision AB (publ) (FRA:C26)

Market Cap	346.67M -25.3%
Revenue (ttm)	67.70M +1.5%
Net Income	13.69M +0.8%
EPS	0.57 +0.8%
Shares Out	n/a
PE Ratio	25.31
Forward PE	21.24
Dividend	0.23 (1.67%)
Ex-Dividend Date	May 7, 2025

Volume	n/a
Average Volume	47
Open	14.10
Previous Close	13.66
Day's Range	14.10 - 14.10
52-Week Range	13.06 - 18.78
Beta	n/a
RSI	49.47
Earnings Date	Feb 5, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1994
• Employees: 231
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C26

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.

Financial numbers in SEK